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Abstract 
Background: The current increase of obesity and metabolic syndrome (MS) focuses attention on bisphenol-A (BPA), 
“obesogen” endocrine disruptor, main plastic component. Aim was to verify the role of BPA in metabolic alterations, 
insulin resistance, low grade inflammation and visceral obesity.
Methods: A cross-sectional study was performed in 76 out of 139 environmentally exposed adult males, unselected 
Caucasian subjects, enrolled by routine health survey at the “Federico II” University of Naples outpatient facilities. 
BPA plasma levels (ELISA), metabolic risk factors, homeostasis model assessment of insulin resistance index, plasma 
monocyte chemoattractant protein 1, interleukin-6 (IL-6) and tumor necrosis factor-alpha were performed. Clinical 
and biochemical parameters have been compared with BPA and pro-inflammatory cytokines levels.
Results: In total 24 subjects out of 76 (32%) presented with waist circumference (WC) >102 cm, 36 (47%) had 
impaired fasting glucose and 24 (32%) subjects had insulin resistance [11 out 52 (21%) with WC ≤102 cm and 13 
out of 24 with WC >102 cm (54%), χ2 6.825, p = 0.009]. BPA and pro-inflammatory cytokine levels were significantly 
higher in subjects with visceral adiposity (WC > 102 cm). BPA correlated with WC, triglycerides, glucose homeostasis 
and inflammatory markers. At the multivariate analysis WC and IL-6 remained the main predictors of BPA.
Conclusions: Detectable BPA plasma levels have been found also in our population. The strictly association between 
BPA and WC, components of MS, and inflammatory markers, further supports the BPA role in visceral obesity-related 
low grade chronic inflammation.
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Background
Obesity epidemics are responsible for the enormous 
strains on our health-care system, also concerning eco-
nomical aspects. It has been proposed that the rapid 
increase in the environment of endocrine disrupting 
compounds (EDCs), in particular bisphenol-A (BPA), can 
be responsible for energy homeostasis disorders [1–3]. In 
this respect, several studies, mainly in animals, evidenced 
the pathogenetic role of BPA in modifying genes involved 
in obesity in  impacting on visceral adipose tissues func-
tion, both processes ending up in metabolic syndrome 
(MS) and cardio-metabolic diseases [3–5].
BPA, as xenoestrogen lipophilic compound, accumu-
lates into adipose tissue [6]. As major plastic compo-
nent, BPA causes a widespread environmental human 
exposure via food and beverage containers, dental 
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composites, thermal paper and airborne dust. Moreo-
ver, it is able to migrate into food and water, mainly 
upon heating [3, 5, 7–10]. BPA is present in body fluids 
of the normal population. In particular, the 2003–2004 
NHANES III conducted by the CDC, found detectable 
levels of BPA in 93% of 2,517 urine samples from peo-
ple 6 years and older [11–13]. Nevertheless, the associa-
tion between urinary BPA and adverse health outcomes 
could be affected by the short half-life of BPA and the 
presence of conjugate and inactive forms of BPA in uri-
nary specimens [14–17]. On the other hand, gender 
differences in serum/plasma BPA concentrations, pos-
sibly due to differences in the androgen-related metabo-
lism of BPA, are well documented, with increase in the 
androgen-related glucuronidation by liver microsomes 
[18]. Although the BPA exposure is decreasing from 
consumer merchandise and by the substitution with bis-
phenol-S, an analog of BPA used in BPA-free products, 
is increasingly, BPA-free products containing BPS are 
not necessarily safer [19].
A number of studies investigated the possible associa-
tion between BPA exposure and adverse health outcomes. 
Indeed, this chemical compound may be involved in adi-
pose tissue dysfunction, but also in metabolic/endocrine 
dysfunctions, cancer and fertility problems [11–16]. As 
collateral finding, a positive association between higher 
levels of urinary BPA and MS parameters, impaired 
plasma glucose has been recently reported [12, 15], such 
as its involvement in insulin resistance, particularly in 
animal models exposed during fetal life [20, 21]. BPA 
plasma levels may be considered a reliable method to 
measure environment-linked chronic exposure [8, 16, 17] 
avoiding interference due to gender and age-relate indi-
vidual differences [18, 22]. Although urine measurement 
is considered the best and easiest way to evaluate BPA, 
a spot of urine sample may not be appropriate to evalu-
ate the real continuous chronic exposure, because largely 
affected by food consumption [7–10, 16–18]. In addition, 
in urine BPA is unstable and mainly in its conjugated and 
inactive form, evaluating only food and beverage con-
tamination and excluding non-oral routes of exposure, 
which avoid the first pass of hepatic metabolism [22–24]. 
Finally, a clear effect of time of exposure and age-depend-
ent differences in metabolic clearance might be responsi-
ble for different effects of BPA on human health [16, 17, 
25]. On the ground of this evidence, we have implanted 
a study in an adult male population living in southern 
Italy with the aim to investigate the association between 
plasma BPA levels and both components of the MS and 
markers of inflammation, considering that the low grade 
chronic inflammation has emerged as a key pathogenic 




A cross-sectional study was conducted on 76 males out 
of 139 unselected Caucasian subjects of both gender 
undergoing a routine health survey at the “Federico II” 
University Hospital of Naples outpatient facilities. All 
the subjects belonged to the workforce of the municipal-
ity of Naples (Italy), representative of the general Italian 
population living in southern Italy, were consecutively 
recruited. The study protocol was approved by the Ethic 
Committee “Carlo Romano” of “Federico II” University of 
Naples and conducted in accordance to the principles of 
the Declaration of Helsinki as revised in 2000. The pur-
pose of the protocol was explained to all participants 
and written consent was obtained at the beginning of the 
study. Exclusion criteria were: (1) female gender due to 
possible interaction of BPA-by-sex; (2) type 2 diabetes 
(T2D) according to the American Diabetes Association; 
(3) renal failure, advanced liver diseases, cancer and acute 
viral, bacterial or fungal infection; (4) acute or chronic 
inflammatory diseases; (5) pharmacological treatments 
potentially impacting on inflammation or acting on 
gluco-lipids metabolism, or appetite modifiers, including 
vitamins and anti-oxidant agents. A balanced antihyper-
tensive regimen was maintained for those suffering from 
hypertension through the study.
Age, race/ethnicity, eating habits, physical activity, 
smoking status, alcohol intake (grams per day), level of 
education and physical activity were assessed using a self-
made written questionnaire, such as the detailed medical 
history (including information on T2D-affected relatives 
and cardiovascular risk).
History, clinical data and blood samples were simulta-
neously collected.
Systolic (SBP) and diastolic (DBP) blood pressure were 
measured in the left arm of the patient, after 5  min of 
quiet rest, using a mercury sphygmomanometer accord-
ing to the American Heart Association recommenda-
tions. Up to three measurements were averaged for SBP 
and DBP.
Anthropometric measurements
All anthropometric measurements were taken with 
subjects wearing only light clothes and without shoes. 
Height was measured to the nearest centimeter using a 
wall-mounted stadiometer. Body weight was determined 
to the nearest 50 g using a calibrated balance beam scale. 
Body mass index (BMI) was calculated as weight (kg)/
height squared (m2) using the following cut off points: 
normal weight 18.5–24.9, overweight 25–29.9, class I 
obesity 30–34.9. WC, as index of visceral adiposity, was 
measured using a flexible steel tape at the natural inden-
tation or at a level midway between the iliac crest and the 
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lower edge of the rib cage if no natural indentation was 
visible.
Blood samples
For each subject, whole-blood samples were drawn 
from an ante-cubital vein in the morning after an over-
night fast on two separate occasions. All plasma samples 
collected were divided in aliquots of 500  µl and trans-
ferred into a clean polypropylene tube, and then stored 
at −80°C until analysis. Total, high-density lipoprotein 
(HDL) and low-density lipoprotein (LDL) cholesterol and 
triglycerides (TG) levels were assayed in a centralized 
facility, using commercial methods. Fasting plasma glu-
cose (FPG) levels were determined by the glucose oxidase 
method. Insulin ELISA was measured by solid-phase 
two-site enzyme immunoassay (Mercodia AB, Sylveni-
usgatan 8A SE-754 50 Uppsala-Sweden). The intra-assay 
and inter-assay coefficients of variation were less than 4 
and 3.6%, respectively.
The homeostasis model assessment index of insu-
lin resistance (HoMA-IR) was calculated according to 
the formula [fasting glucose (mmol/l)  ×  fasting insulin 
(mU/l)/22.5], as previously reported, and HoMA-IR >2.5 
was considered to be diagnostic for IR [27, 28].
Metabolic risk factor assessment
Metabolic risk factors were defined according to The 
National Cholesterol Education Program’s Adults Treat-
ment Panel III (NCEP-ATP III) revised criteria [29], 
i.e. WC  >  102  cm; TG  >  150  mg/dl; HDL  <  40  mg/dl; 
SBP > 130 mmHg or DBP > 85 mmHg and fasting plasma 
glucose >100 mg/dl.
Markers of inflammation
Plasma monocyte chemoattractant protein 1 (MCP-1), 
interleukin-6 (IL-6) and tumor necrosis factor-alpha 
(TNFα) were measured using an Human BIO-PLEX Sus-
pension Array Multi-panel System (BIORAD Laborato-
ries, Inc.), according to the manufacturer’s protocol.
BPA assay
Total plasma concentrations of BPA (free and conjugated) 
were assayed with a kit from IBL Co. (Ltd., Gunma, 
Japan), based on a competitive ELISA protocol, using 
the anti-rabbit IgG antibody solid-phase method and 
characterized by a measurement range of 0.3–100 ng/ml 
BPA. To better sensitize this ELISA method on plasma 
samples, we have modified the standard curve, obtain-
ing a BPA low limit of detection of 0.025 ng/ml. The cross 
reactivity for total BPA was 100%, for BPA-Glucuronide 
85%, for BPA–Na-Sulphate 68%, for Bisphenol B 8.3%, 
and for other related compounds less that 0.02%. The 
intra- and inter-assay coefficients of variation (CV) were 
<14 and 5%, respectively. All standards and samples were 
measured in duplicate. As low and high internal control, 
we used a control plasma added with BPA 1 and 25 ng/
ml, respectively.
Statistical analysis
Results are expressed as mean ±  SD or as median plus 
range according to variable distributions, as indicated. 
Differences in variables between groups were analyzed 
using the unpaired Student t test or Mann–Whitney U 
test, when appropriate. Pearson r or Spearman’s rho cor-
relation coefficients were used to analyze the association 
between variables. Frequencies among groups were ana-
lyzed by χ2 for trend. In suspicion of heteroscedasticity, 
i.e., if there are sub-populations that have different varia-
bility from others in the homoscedastic model and having 
detected the presence of few outliers, to avoid a dramatic 
increase in the type II error rate, we analyzed the cor-
relation between BPA and WC by the robust regression. 
The method for estimating the parameters (coefficient, 
standard error and 95% confidence intervals, CI) in a lin-
ear regression model was ordinary least squares (OLS) 
[30]. Using BPA as dependent variable, a multiple lin-
ear regression analysis model was performed with the 
enter selection methods: in this model WC, HoMA-IR, 
IL-6, and TNFα were included as independent variables. 
A t-stat >1.96, with a significance <0.05, indicates that 
the independent variable is a significant predictor of the 
dependent variable within and beyond the sample. To 
avoid multicollinearity, i.e. situations in which the pre-
dictors are correlated to each other to some degree, the 
variance inflation factor and tolerance were set to >10 
and <0.1, respectively. P value <0.05 was considered sta-
tistically significant. Packages used for running statistics 
were SYSTAT 13 (2009) and MedCalc 14.8.1 (2014).
Results
Subjects: clinical and metabolic parameters
Clinical and biochemical markers of the study population 
was reported in Table 1. According to BMI cut off points, 
36 subjects presented with normal weight, 28 were over-
weight and 12 had class I obesity.
In the whole population, 24 subjects (32%) presented 
with visceral adiposity (WC  >  102  cm), while 34 (45%) 
and 27 (36%) subjects had increased SBP and DBP, 
respectively. Forty subjects (53%) were euglycemic and 
the remaining 36 had impaired fasting glucose, while val-
ues of HoMA-IR >2.5 were found in 24 subjects (32%). 
The minimum and maximum BPA plasma values of the 
our study population were 0.04 and 3.3  ng/ml, respec-
tively, with a mean value in line with other population 
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studies. In particular, considering the median BPA value 
(0.94 ng/ml), the diagnosis of MS was made in four sub-
jects (11%) with low BPA vs 16 (42%) with high BPA (χ2 
8.211; p = 0.0042) (Figure 1).
Dividing the population according to WC (Table  2), 
there were significant differences in BMI, HDL, insulin, 
HoMA-IR, as expected. In particular, 11 subjects out 
of 52 (21%) with WC ≤  102  cm and 13 out of 24 with 
WC  >  102  cm (54%) were insulin-resistant (χ2 6.825; 
p = 0.009). In addition, BPA (p = 0.002), IL-6 (p = 0.030) 
and TNFα (p = 0.007) levels were significantly higher in 
the subjects with WC >102 cm.
Correlation studies
Next, we searched for correlations between BPA plasma 
levels and clinical and metabolic parameters in the whole 
study population (Table 3). BPA levels were significantly 
correlated with WC, TG, and markers of glucose homeo-
stasis (FPG, insulin, HoMA-IR). In addition, significant 
correlations were found between BPA and inflammatory 
markers, such as IL-6 and TNFα. At robust regression, a 
strict prediction by BPA towards WC was found with the 
following results: coefficient 0.033, standard error 0.008, 
CI 0.017–0.048 (Figure  2). At the multivariate analy-
sis WC and IL-6 remained the main predictors of BPA 
(Table 4).
Discussion
In the present study we have obtained evidence that the 
adult males living in Southern Italy have detectable BPA 
Table 1 Clinical and biochemical parameters  of the study 
population
Data are expressed as mean ± standard deviation or median, according to vari-
able distribution. In particular, SBP, DBP, insulin, HoMA-IR, IL-6 and TNFα were 
expressed an median with range.
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP 
diastolic blood pressure, FPG fasting plasma glucose, HoMA-IR homeostasis 
model of assessment-insulin resistance, HDL high-density lipoprotein, LDL low-
density lipoprotein, TG triglycerides, BPA bisphenol-A, IL-6 interleukin-6, MCP-1 
monocyte chemoattractant protein-1, TNFα tumor necrosis factor-alpha.
Parameters Values
Age (years) 53.5 ± 5.7
BMI (kg/m2) 25.7 ± 3.4
WC (cm) 96.8 ± 10.1
SBP (mmHg) 120 (90–160)
DBP (mmHg) 80 (60–100)
FPG (mg/dl) 100.9 ± 11.8
Insulin (mU/l) 6.1 (1.2–28.7)
HoMA-IR 1.4 (0.4–8.4)
Total cholesterol (mg/dl) 208.1 ± 46.1
HDL (mg/dl) 49.8 ± 11.7
LDL (mg/dl) 129.8 ± 42.1
TG (mg/dl) 154.6 ± 73.6
BPA (ng/ml) 1.04 ± 0.77
IL-6 (pg/ml) 0.77 (0.06–3.43)
MCP-1 (pg/ml) 27.4 ± 23.5
























Figure 1 Percentage of patients affected by metabolic syndrome 
(MS) in the two groups divided considering the median bisphenol-A 
(BPA) plasma value of 0.94 ng/ml. Four subjects out of 38 (11%) in the 
group with BPA plasma levels <0.94 ng/ml have MS, while 16 out of 
38 (42%) were MS positive (MS+) in the group with BPA plasma levels 
>0.94 ng/ml.
Table 2 Clinical and biochemical parameters  of the study 
population according to waist circumference
Data are expressed as mean ± standard deviation or median, according to vari-
able distribution. In particular, SBP, DBP, Insulin, HoMA-IR, IL-6 and TNFα were 
expressed as median with range. Differences in variables between groups were 
analyzed using the unpaired Student t test or Mann-Whitney U test, when 
appropriate.
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP 
diastolic blood pressure, FPG fasting plasma glucose, HoMA-IR homeostasis 
model of assessment-insulin resistance, HDL high-density lipoprotein, LDL low-
density lipoprotein, TG triglycerides, BPA bisphenol-A, IL-6 interleukin-6, MCP-1 
monocyte chemoattractant protein-1, TNFα tumor necrosis factor-alpha.





Age (years) 53.6 ± 6.0 53.4 ± 5.2 0.900
BMI (kg/m2) 24.0 ± 2.5 29.1 ± 2.5 <0.0001
SBP (mmHg) 122.5 (90–160) 120.0 (100–160) 0.819
DBP (mmHg) 80.0 (65–95) 80.0 (60–100) 0.305
FPG (mg/dl) 101.4 ± 12 99.9 ± 11.7 0.613
Insulin (mU/l) 3.6 (1.2–26.4) 10.4 (3.3–28.7) 0.0006
HoMA-IR 0.9 (0.4–7.7) 2.7 (0.7–8.4) 0.0016
Total cholesterol 
(mg/dl)
212.0 ± 50.1 199.5 ± 35.2 0.273
HDL (mg/dl) 52.7 ± 11.8 43.6 ± 9.1 0.001
LDL (mg/dl) 132.9 ± 46.5 123.0 ± 30.2 0.344
TG (mg/dl) 149.8 ± 81.5 165.0 ± 53.4 0.407
BPA (ng/ml) 0.86 ± 0.72 1.44 ± 0.74 0.002
IL-6 (pg/ml) 0.77 (0.06–2.2) 0.78 (0.07–3.43) 0.030
MCP-1 (pg/ml) 26.9 ± 25.4 28.3 ± 19.3 0.808
TNFα (pg/ml) 1.1 (0.5–9.1) 3.2 (0.6–8.3) 0.007
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plasma levels. In addition, we found that higher BPA 
plasma levels were associated with higher WC and TG 
values and with alteration in glucose homeostasis. In this 
respect, our data are generally confirmatory of the lit-
erature on the wide diffusion of the BPA environmental 
exposure among different populations and on the asso-
ciation of this exposure with the MS and visceral adi-
posity in humans [4, 8, 12, 13, 15]. Furthermore, higher 
BPA levels were associated with higher circulating IL-6 
and TNFα levels, usually considered as useful markers 
of low grade inflammation related to visceral adipos-
ity. MCP-1, marker of chronic inflammation involved in 
endothelial dysfunction, hypertension and cardiovascu-
lar risk in obese subjects, did not changed. Although the 
statistically significant difference in circulating cytokines 
not necessarily bears a biological significance, to the best 
of our knowledge this study reports the first evidence 
of the association between BPA plasma levels, markers 
of visceral adiposity dysfunction and inflammation in 
adult males. Previous studies investigated the associa-
tion between BPA and altered glucose homeostasis [7, 8, 
11, 14, 15]. The strong correlation between BPA, WC, 
IL-6 and TNFα plasma levels supports the pathogenetic 
involvement of BPA in increasing visceral adiposity and 
determining low grade chronic inflammation.
Of interest, in our study visceral adiposity and inflam-
mation, but not HoMA-IR, were the main predictors of 
BPA plasma levels. This association let us to speculate 
that the well-known correlation between altered glucose 
homeostasis and BPA could be only the epiphenomenon 
of the association between BPA and visceral adiposity 
dysfunction, with inflammation as marker of this asso-
ciation. This evidence further support the hypothesis 
that in individuals with BPA environmental exposure, 
the derangement of glucose metabolism and inflamma-
tory pathways might be associated independently from 
the inflammatory pathways induced by visceral adiposity 
per se. In line with data by Teppala et  al. [12] obtained 
in a representative sample of US adults, we also found 
that higher prevalence of MS occurred in subjects with 
higher BPA plasma levels. As support for the direct 
involvement of BPA in inflammatory and dysmeta-
bolic processes in vivo, we have recently obtained evi-
dence in vitro on adipocyte cultured with BPA doses (1 
nM = 23 ng/ml) considered low in cultured cells, but in 
Table 3 Correlations between BPA and clinical and meta-
bolic parameters
Pearson r or Spearman’s rho correlation coefficients were used to analyze the 
association between variables.
Italic r values are Pearson r or Spearman’s rho correlation coefficients, when 
appropriate. Italic p values are statistically significant.
BMI body mass index, WC waist circumference, SBP systolic blood pressure, DBP 
diastolic blood pressure, FPG fasting plasma glucose, HoMA-IR homeostasis 
model of assessment-insulin resistance, HDL high-density lipoprotein, LDL low-
density lipoprotein, TG triglycerides, BPA bisphenol-A, IL-6 interleukin-6, MCP-1 

















Figure 2 The correlation between bisphenol-A (BPA ng/ml) and 
waist circumference (WC cm) was analyzed by the robust regression. 
A strict prediction by BPA towards WC was found.
Table 4 Multivariate analysis
Using bisphenol-A as dependent variable, a multiple linear regression analy-
sis model was performed with the enter selection methods: in this model WC, 
HoMA-IR, IL-6, and TNFα were included as independent variables. Variable 
excluded: HoMA-IR and TNFα.
WC waist circumference, IL-6 interleukin-6.
Parameters β t p
WC 0.298 2.674 0.008
IL-6 0.237 2.123 0.037
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the range of typical human exposure. These adipocytes 
displayed an activation of inflammatory pathways and 
alteration of insulin signaling [31]. However, additional 
in vitro experimental studies, particularly on adipogen-
esis, are necessary in order to unravel how BPA continu-
ous environmental exposure can act on adipose tissue 
differentiation with subsequent dysfunction and altera-
tion in glucose and lipid homeostasis, affecting human 
metabolic health.
Concerning human BPA exposure, we have also dem-
onstrated that in women with polycystic ovary syndrome 
(PCOS), a condition typically characterized by IR and 
low grade chronic inflammation, the association between 
BPA plasma levels and markers of low grade inflamma-
tion, in particular spleen size, a reliable and a stable index 
of chronic inflammation, occurred independently of obe-
sity. In the same study, higher BPA levels identified a sub-
group of PCOS women characterized by higher markers 
of low grade chronic inflammation, increased prevalence 
of hepatic steatosis, and more severe IR and hyperandro-
genism [32].
We are aware that the main limitation of this study 
is the relatively small sample size for a cross sec-
tional study, but it was not simple to acquire a large 
homogenous cohort in short time, also because we 
have included only environmentally exposed adult 
males from Caucasian unselected homogeneous pop-
ulation. This aspect suggests that future studies with 
larger sample size are needed. However, the strength 
of this study was the homogeneity of the population 
sample, including only adult male participants of the 
same ethnic group, geographic area and occupancy, 
to avoid the confounding effects on gender, race, time 
and modality of environmental BPA exposure. Fur-
thermore, although BPA plasma levels may be consid-
ered a reliable method to measure chronic exposure, 
there is a recent tendency to prefer urine as the most 
appropriate and robust marker for BPA exposure 
assessment.
Conclusions
The evidence that individuals in the world have measur-
able plasma levels of BPA is now confirmed also in our 
adult population living in southern Italy. The subjects 
with higher BPA plasma values presented markers of low 
grade inflammation, higher visceral adiposity and higher 
prevalence of MS and insulin resistance.
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